In the subgroup of patients with hormone receptor-positive HER2-negative breast cancer treated with neratinib and fulvestrant, four (24% [95% CI 7–50]) of 17 patients had a confirmed response (figure 3). This evidence concerns the gene NR4A1 and breast carcinoma.